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ABSTRACT 
 
Introduction: Use of SPECT/CT data is the most accurate method for patient-specific internal dosimetry when isotopes emit 
single gamma rays. The manual or semi-automatic segmentation of organs is a major obstacle that slows down and limits the 
patient-specific dosimetry. Using digital phantoms that mimic patient’s anatomy can bypass the segmentation step and 
facilitate the dosimetry process. In this study, the results of a patient-specific dosimetry based on CT data and XCAT phantom, 
a flexible phantom with predefined organs, are compared.  
Methods: The dosimetry results (S-value and SAF) were calculated for a patient with breast cancer who received Samarium-
153 ethylenediamine-N,N,N′,N′-tetrakis(methylenephosphonic acid (153Sm-EDTMP). Biodistribution of activity was obtained 
from the SPECT scan. The anatomical data and attenuation map were extracted from CT as well as the XCAT phantom with 
different BMIs. GATE Monte-Carlo simulator was used to calculate the dose to different organs based on the activity 
distribution and segmented anatomy.  
Results: The whole body dosimetry results are the same for both calculations based on the CT and XCAT with different BMIs; 
however for target organs, the differences between SAFs and S-values are high. In the spine, the clinically important target 
organ for Samarium therapy, the dosimetry results obtained from phantoms with unmatched BMIs between XCAT phantom 
and CT are substantially different. 
Conclusion: We showed that atlas-based dosimetry using XCAT phantom even with matched BMI may lead to considerable 
errors as compared to calculations based on patient’s own CT. For accurate dosimetry results, calculations should be done 
using CT data. 
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INTRODUCTION 
Image-based internal dosimetry has been a major area 
of research over recent years [1-4]. Patient-specific 
dosimetry is the most accurate method for systemic 
radiation treatment planning [5, 6]. Specific 
information is required including activity distribution 
and organ boundaries for patient-specific dosimetry. 
CT data provides anatomical information which can be 
used for defining volume of interests specifying 
internal organs. Hybrid SPECT/CT functional 
imaging allows the lesions visible in functional 
imaging modality to be correlated with anatomical 
structures [7]. For internal dosimetry purposes, 
SPECT/CT provides anatomical and functional 
imaging in a single session and has the important 
option for SPECT activity quantification and the data 
of both biodistribution of the activity and the anatomy 
of the organs being collected simultaneously [8]. 
Nevertheless, using CT images for segmentation of 
anatomic structures of patient body, despite being 
more accurate, is time consuming. The alternative is 
using phantoms or atlas data with already segmented 
organs and known organ boundaries. The anatomical 
structures are derived from these databases very 
easily. However, the variability of radiotracers’ 
biodistribution and differences of anatomical 
structures are remarkable among patients which hinder 
accurate application. Newly developed sophisticated 
humanoid phantoms may fit more with the patient’s 
specifications and overcome this obstacle. The 4D-
extended cardiac-torso (XCAT) phantom [9] is a 
flexible phantom that can be used for different 
purposes. XCAT phantoms can be generated for both 
genders with different resolutions and voxel sizes and 
for different body mass indices (BMI). The critical 
concern which will be addressed in this paper is 
whether the results are similar to methods that use 
patient’s CT. In this research, we address this concern 
through an experimental study. The CT data was 
obtained from a patient treated with Samarium-153 
ethylenediamine-N,N,N′,N′-
tetrakis(methylenephosphonic acid (153Sm-EDTMP) 
for multiple bone metastases from breast cancer. 
153Sm-EDTMP is used for pain palliation therapy in 
end stage patients with intractable bone pain [10]. 
For dosimetry calculations GATE (GEANT4 
Application to Tomographic Emission) [11], a Monte 
Carlo based script interface dedicated to nuclear 
medicine, was used. Different versions of this free 
open source toolkit are available on the openGATE 
collaboration website. It was primarily developed for 
simulation of imaging processes of PET, SPECT [11, 
12] and CT [13, 14] and it is validated for internal dose 
calculations [15]. For dosimetry applications, GATE 
is capable to take either patient’s CT or a digital atlas 
phantom as input [16]. GATE has certain attractive 
features; some of them are inherited from GEANT4 
[17] and some are additionally developed. These 
include flexible simulation geometry capable of 
accommodating a large variety of detector and source 
details and the physical events. The software provides 
a user-friendly voxelized source, a virtual clock 
allowing to simulate temporal phenomena such as 
source and detector movements and source decay, and 
a large variety of physical models (i.e. photo-nuclear 
and photo-media reactions). Using GATE, we 
compared the specific absorbed fraction (SAF) and S-
values (the mean absorbed dose to the target organ 
from unit activity of the relevant radioisotope 
distributed within the source organ/s) for gamma and 
beta emissions from 153Samarium using a patient’s CT 
and XCAT phantom with either matched or 
unmatched BMIs. 
 
METHODS 
Patient study 
A 50 year old female now passed away with 
widespread bone metastases from breast cancer was 
slowly injected with 150 mCi activity of 153Sm-
EDTMP intravenously. The patient had a BMI of 38.3. 
Eighteen hours after the tracer injection, patient 
underwent SPECT/CT imaging. The Simens Simbia T 
SPECT/CT scanner was used for the imaging. 
SPECT/CT images between the chest and the 
abdomen were obtained. For SPECT imaging, 64 
projections were acquired with 20 second per 
projection. The matrix size of SPECT was 64×64 with 
pixel size of 9.59 mm. The low dose CT component, 
with the arc of 360,̊ 130 kVp and 30mA, was used. The 
CT image provided an attenuation map for attenuation 
correction and aided the localization of organs. 
SPECT reconstruction was performed using iterative 
ordered-subsets expectation maximization algorithm 
(OSEM). The reconstruction used 8 iterations and 4 
subsets, Gaussian diffusion resolution recovery and 
CT-based attenuation correction. For the SPECT 
image, all the available corrections was done including 
the main one, attenuation correction. We also 
performed calibration for Samarium. Absorbed dose 
estimation requires longitudinal studies and several 
imaging. Our study addresses the effect of anatomical 
differences on S-values which is a dosimetric 
parameter and related to the absorbed dose. SPECT 
and CT image fusion was performed with SPECT/CT 
fusion software automatically and with manual fine 
tuning afterwards. 
The semi-automatic segmentation of the organs in the 
CT image was performed using itk-SNAP [18] 
(version 2.4.0) software. Eight organs that are 
important in Samarium therapy were segmented in 
addition to the body as a whole. Validations are 
performed by comparison between segmented organs 
and organs in patient’ CT image visually. An ID was 
assigned to each organ which was used as input to 
GATE. We assigned each segmented organ ID the 
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corresponding material to be used for dosimetry using 
GATE [19].   
 
XCAT phantom study 
XCAT phantom is a CT based-hybrid phantom that 
have some capability to replicate some characteristics 
of the real patients but not all. We changed as many 
characteristic as possible in XCAT including selecting 
the most fitted BMI to produce the phantom that has 
the most similarity to our patient. The XCAT phantom 
was generated based on the patients characteristics 
(female with BMI= 38.8 and right side mastectomy) 
and CT specification (matrix size and voxel size). The 
following parameters were employed: 64×64 for 
matrix size, 60 for number of slices and 9.59 mm for 
voxel size (Figure 1). We also designed XCAT 
phantoms with BMIs of 36.7 and 35.5 and compared 
them with the results from patient BMI matched 
phantom. Different numbers were assigned to XCAT 
different organs so that every organ had a unique ID 
number. Corresponding μ values were mapped later 
from the GATE material data base.  
 
Monte Carlo simulation 
For both simulations of patient-specific dosimetry 
with the CT and XCAT phantom, the same SPECT 
image was used as the activity map. The simulations 
were performed in GATE Monte Carlo code (version 
6.0.0). The data of SPECT, CT and XCAT phantoms 
were processed to prepare suitable input file formats 
for GATE. The results of the internal dosimetry for the 
real activity distribution in the patient body based on 
the SPECT data were calculated for the CT image and 
the XCAT phantom in the kidney, liver, heart, spleen, 
bladder, lung, ribs, and spine as well as in the total 
body. Photoelectric absorption, Compton and 
Reyleigh scattering, ionizations, multiple scattering 
and bremsstrahlung photons were simulated. After 
completion of simulations, GATE produced two 
binary files, containing respectively the absolute 
absorbed dose delivered into the voxels (in cGy) and 
the corresponding uncertainties [20]. The uncertainty 
is the relative statistical error and expressed as a 
fraction between 0 and 1. 
 
Dosimetry calculations 
The results of dosimetry calculations are presented 
according to Medical International Radiation Dose 
(MIRD) committee formalism [21]; specific absorbed 
fraction (SAF) was calculated as the fraction of energy 
emitted by the radioisotope in the source organ (rs), 
that is absorbed in the target organ (rt) per unit mass of 
the target organ (mt). 
𝑆𝐴𝐹(𝑟𝑡 ← 𝑟𝑠) =
𝑟𝑡
𝑟𝑠⁄
𝑚𝑡
 
The S-value has a unit of mGy/MBq-s. In theory, the 
relation is given by 𝑆 = ∑ Δi ×  SAF𝑖 , where Δi is the 
mean energy of the ith transition per nuclear 
transformation of a specific isotope [22]. Since we are 
comparing results from monoenergetic particles, the 
relation reduces to S = E × SAF, where E is the energy 
of the 153Samarium. 
 
 
Fig 1. A typical transverse slice of CT image and XCAT phantom; 
a) Patient’s CT, b) BMI 38.8, c) BMI 36.7 and d) BMI 35.5. 
 
RESULTS 
It is common that the results of the dosimetry are 
reported in SAF for gamma radiation and S-value for 
the beta emission. Given Samarium-153 has both 
decay mode, we reported SAF for 103 keV gamma 
radiation and S-value for 0.801 MeV beta emission. 
The SAFs for gamma and S-values for beta emissions 
are presented in Table 1. The organ of interest for this 
particular radiotracer is the spine. The S-value for the 
spine, is 1.83e-05 when patient CT is used and 
0.84580e-5 when XCAT phantom with BMI=38.8 is 
employed, also the SAF for the spine is 0.0566 using 
CT data and 0.0414 using XCAT phantom. The 
difference in SAFs and S-value for the spine is 26.8% 
and 53.8% respectively. The highest differences in the 
S-values are observed for the ribs (70.7%) and bladder 
(-109%). The highest difference among the SAFs is for 
the liver (27.6%). 
The results of two other different BMIs (i.e. 36.74 and 
35.53) are presented in Table 2. For the XCAT 
phantom with BMI 36.7, the differences in SAFs and 
S-values for the spine are 21.5% and 49% 
respectively. The highest differences in S-values are 
observed for the ribs (73.8%) and bladder (-64.4%). In 
XCAT phantom with BMI 35.53 the difference in 
SAFs and S-values for the spine is 23.8% and 47.4% 
respectively. The highest difference in S-value is 
observed in the ribs (79.6%). The difference in the S-
value of bladder (-16.9%) is the smallest amongst the 
3 BMIs that we tested. 
153Sm dosimetry: Image-based vs. atlas-based 
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Table 1: The SAF and S-value in different organs 18 hours after administration of 150mCi 153Sm; comparison between dosimetry based on 
CT and XCAT phantom with BMI of 38.8. The source of activity is the SPECT.  
 
Organs 
SAF(1/kg) 
Difference (%) 
S-Value (mGy/MBq.S) 
Difference (%) 
CT 
XCAT with 
BMI38.8 
CT 
XCAT with 
BMI38.8 
Lung 0.0130 0.0114 12.3 7.11e-06 7.3915e-06 -3.90 
Liver 0.0123 0.0089 27.6 2.90e-06 1.9503e-06 32.7 
Kidney 0.0153 0.0123 19.6 1.94e-06 1.3962e-06 28.0 
Spleen 0.0103 0.0117 -13.5 1.43e-06 1.2816e-06 10.4 
Spine 0.0566 0.0414 26.8 1.83e-05 8.4580e-06 53.8 
Rib Bone 0.0316 0.0265 16.1 4.68e-06 1.3706e-06 70.7 
Bladder 0.0145 0.0103 28.9 1.64e-06 3.4215e-06 -109 
Heart 0.0101 0.0087 13.8 1.09e-06 1.3788e-06 -26.5 
Whole Body 0.0086 0.0081 5.8 2.0646e-06 2.0842e-06 -0.9 
 
 
 
Table 2: The SAF and S-value in different organs 18 hours after administration of 150mCi 153Sm; comparison between CT and XCAT with 
BMI 36.7 and 35.5 calculation. The source of activity is the SPECT. 
 
Organs 
SAF(1/kg) S-Value (mGy/MBq.S) 
XCAT with 
BMI36.7 
Difference 
(%) 
XCAT with 
BMI35.5 
Difference 
(%) 
XCAT with 
BMI36.7 
Difference 
(%) 
XCAT with 
BMI35.5 
Difference 
(%) 
Lung 0.0115 11.5 0.0093 28.4 6.7758e-06 4.7 6.0205e-06 15.3 
Liver 0.0087 29.2 0.0090 26.8 1.9718e-06 32 2.2090e-06 23.8 
Kidney 0.0106 30.7 0.0119 22.2 1.1123e-06 42.7 1.6672e-06 14.1 
Spleen 0.0100 2.9 0.0099 3.8 1.3982e-06 2.2 1.3855e-06 3.1 
Spine 0.0444 21.5 0.0431 23.8 9.3374e-06 49 9.6234e-06 47.4 
Rib Bone 0.0264 16.4 0.0193 38.9 1.2278e-06 73.8 9.5588e-07 79.6 
Bladder 0.0116 20 0.0121 16.5 2.6963e-06 -64.4 1.9177e-06 -16.9 
Heart 0.0087 13.8 0.0088 12.8 1.7246e-06 -58.2 1.9161e-06 -75.8 
Whole Body 0.0086 0 0.0084 2.3 2.3717e-06 -14.8 2.1852e-06 -5.8 
 
The differences between the calculations based on CT 
and XCAT phantoms for all BMIs in kidney, liver, 
heart, spleen, bladder, lung, ribs and spine are 
considerable (Figures 2 & 3). As illustrated in the 
figures, the radiation to the spine is considerably 
higher when the CT data is used compared to XCAT; 
nevertheless, the whole body dosimetry results and the 
dosimetry of the lungs, liver, spleen and kidneys are 
rather the same between the calculations based on the 
CT data and the XCAT with different BMIs. 
 
DISCUSSION 
We observed similar whole body dosimetry results 
based on XCAT phantom with different BMIs and 
patient’s CT data but remarkable differences between 
the dosimetry results for various organs (Table 1). 
These differences are higher than the acceptable 
variation of dosimetry results for clinical use [23]. The 
differences did not increase when unmatched BMI 
XCAT phantoms were used (Figures 2 & 3) which 
indicates that factors other than solely BMI are 
important in these calculations. Considering patient-
specific dosimetry as the most available accurate 
method, our results show calculations on BMI 
matched XCAT phantom has remarkable differences 
from the CT based dosimetry. Hence, the whole body 
dosimetry is valid when calculations are done based 
on XCAT data instead of patient’s CT, but the S-value 
and the SAF to the target organs may not be used 
interchangeably. 
 
153Sm dosimetry: Image-based vs. atlas-based 
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Fig 2. Comparison between SAFs of CT and XCAT phantom with 
different BMIs. 
 
 
 
 
Fig 3. Comparison between S-values of CT and XCAT phantom 
with different BMIs. 
 
The differences in the dosimetry results using the 
patient’s individual CT and XCAT phantom were 
substantial in all employed BMIs. Similarity between 
the BMI used for XCAT design and patient did not 
decrease the extent of the error. Shape and size of the 
organs and the body composition may play a 
significant role in this regard. Given that the phantoms 
are based on the body composition of an individual 
subject, extrapolation to all patients is questionable. 
The differences in S-values infer that the patient’s CT 
data cannot be safely substituted by XCAT phantom 
for calculation of the radiation of beta particle which 
exerts the therapeutic effect of the systemic radiations 
therapy [24]. The radiation to the spine and ribs could 
be underestimated when the XCAT data is employed 
(Figures 2 & 3). Also the absorbed doses in the lung 
and liver are underestimated with a lesser extent. The 
underestimation of the dose to the favorable target 
organs may cause overtreatment and increased risk of 
unfavorable side effects. 
The similarity of the whole body dosimetry shows that 
the phantom and the calculation/simulations are 
generally acceptable. Variation between the organ 
boundaries and geometry of organs between patient 
and phantom may cause the differences and affect the 
organ dosimetry. On the other hand the quality of the 
segmentation of the organs in the CT image may 
contribute to finding; if the organs are not perfectly 
chosen the dosimetry would not be the real dosimetry 
for the organ.  
In this study we used the GATE Monte Carlo code for 
calculation of absorbed dose. GATE code is already 
validated for dosimetry in many clinical situations 
including brachytherapy, external beam radiotherapy 
with photons/electrons, systemic radiotherapy, and 
proton-therapy. One of the main privileges of GATE 
is the capability to support both imaging and therapy 
modeling procedures [25]. The method we used has 
been employed with variations in other studies [26] for 
example to study mathematical phantom derived from 
the MIRD-type adult phantom. 
The use of phantoms is already validated for internal 
dosimetry purposes [15, 20]. We previously reported 
that the dosimetry based on XCAT phantom is 
different from those based on the Zubal phantom [27] 
as well as different dosimetry estimations obtained 
from different XCAT BMIs [28, 29]. We showed that 
the differences corresponded to the different organ 
sizes. Hence, the different organ sizes between the 
patient and the phantom may affect the dosimetry and 
describes at least a part of denoted differences in the 
current study. 
 
CONCLUSION 
In this study, we showed that the results of dosimetry 
vary when the XCAT phantom is used in place of 
patient’s CT image and the extent of the differences 
varies among XCAT phantoms with different BMIs. It 
seems that for treatment planning either we still need 
more accurate patient-specific dosimetry with patient 
own CT data, or humanoid phantoms need more 
adaptation to patient’s characteristics.  
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